Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins

Use of recombinant human proteins has revolutionized medicine by providing over 200 highly purified hormones and proteins that effectively treat many inherited and acquired peptide hormone and protein deficiencies. With the exception of therapeutic monoclonal antibodies, these biological medicines a...

Full description

Saved in:
Bibliographic Details
Published inThrombosis and haemostasis Vol. 99; no. 5; p. 874
Main Authors Mukovozov, Ilya, Sabljic, Thomas, Hortelano, Gonzalo, Ofosu, Frederick A
Format Journal Article
LanguageEnglish
Published Germany 01.05.2008
Subjects
Online AccessGet more information

Cover

Loading…
Abstract Use of recombinant human proteins has revolutionized medicine by providing over 200 highly purified hormones and proteins that effectively treat many inherited and acquired peptide hormone and protein deficiencies. With the exception of therapeutic monoclonal antibodies, these biological medicines are synthesized by cultured cells using DNA sequences that would yield proteins with identical amino acid sequences as endogenous human proteins. Therefore, there was the broad expectation that recombinant human biological medicines would be non-immunogenic in patients capable of synthesizing even sub-optimal levels of these therapeutic proteins to which they are innately tolerant. However, the widespread clinical use of recombinant human proteins has demonstrated that nearly all of them are immunogenic. This observation suggests that factors additional to differences in amino acid sequences of endogenous and biotherapeutic proteins contribute to the immunogenicity of therapeutic proteins. The main aim of this review is to summarize some of the factors that are known to contribute to the immunogenicity of recombinant therapeutic proteins.
AbstractList Use of recombinant human proteins has revolutionized medicine by providing over 200 highly purified hormones and proteins that effectively treat many inherited and acquired peptide hormone and protein deficiencies. With the exception of therapeutic monoclonal antibodies, these biological medicines are synthesized by cultured cells using DNA sequences that would yield proteins with identical amino acid sequences as endogenous human proteins. Therefore, there was the broad expectation that recombinant human biological medicines would be non-immunogenic in patients capable of synthesizing even sub-optimal levels of these therapeutic proteins to which they are innately tolerant. However, the widespread clinical use of recombinant human proteins has demonstrated that nearly all of them are immunogenic. This observation suggests that factors additional to differences in amino acid sequences of endogenous and biotherapeutic proteins contribute to the immunogenicity of therapeutic proteins. The main aim of this review is to summarize some of the factors that are known to contribute to the immunogenicity of recombinant therapeutic proteins.
Author Mukovozov, Ilya
Sabljic, Thomas
Ofosu, Frederick A
Hortelano, Gonzalo
Author_xml – sequence: 1
  givenname: Ilya
  surname: Mukovozov
  fullname: Mukovozov, Ilya
  organization: Department of Pathology and Molecular Medicine, McMaster University, 1200 Main Street West, HSC 3N26, Hamilton, ON, Canada L8N 3Z5
– sequence: 2
  givenname: Thomas
  surname: Sabljic
  fullname: Sabljic, Thomas
– sequence: 3
  givenname: Gonzalo
  surname: Hortelano
  fullname: Hortelano, Gonzalo
– sequence: 4
  givenname: Frederick A
  surname: Ofosu
  fullname: Ofosu, Frederick A
BackLink https://www.ncbi.nlm.nih.gov/pubmed/18449416$$D View this record in MEDLINE/PubMed
BookMark eNo1j81KAzEYRbOo2B_duZa8wGi-JJOZWUqxVii4qeCu5OcbGzHJkMks-vZWtKsD58CFuySzmCIScgfsAUCxx_2WNRVAxVQtZ2TBhGSV4rKek-U4fjEGSnb1NZlDK2UnQS3Ix0bbkvJIy1EXalMs2ZupIC3prJD6EMIU0ydGb3050dT_6qwHnIq3NKNNwfioY6HHKehIh5wK-jjekKtef494-88Ved8879fbavf28rp-2lVWQVMqYU3Xdhp544AbKxoO6NACuNoIFL3QSrrayVowwXuwlhuArjlHLVvFga_I_d_uMJmA7jBkH3Q-HS4X-Q_IcFQZ
CitedBy_id crossref_primary_10_1002_jps_22276
crossref_primary_10_1016_j_cbpa_2009_04_627
crossref_primary_10_1002_jps_22123
crossref_primary_10_1586_17474086_2014_963550
crossref_primary_10_1517_17425240903199143
crossref_primary_10_4161_mabs_1_2_7909
crossref_primary_10_1155_2016_1298473
crossref_primary_10_4155_bio_2020_0174
crossref_primary_10_1111_j_1365_2516_2009_02058_x
crossref_primary_10_1126_science_abe0075
crossref_primary_10_1016_j_chroma_2009_10_057
crossref_primary_10_1016_j_ejpb_2009_02_014
crossref_primary_10_1517_17425250802525496
crossref_primary_10_1021_ac3026465
crossref_primary_10_1002_pro_680
crossref_primary_10_1016_j_molimm_2021_05_005
crossref_primary_10_1057_jgm_2010_10
crossref_primary_10_1016_j_bbamcr_2009_01_007
crossref_primary_10_1016_j_exphem_2009_02_011
crossref_primary_10_1017_cts_2020_493
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1160/TH07-11-0654
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
ExternalDocumentID 18449416
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GroupedDBID ---
.55
.GJ
0R~
0VX
123
1KJ
4.4
53G
5RE
AAQQT
ABJNI
ABOCM
ACGFO
ACGFS
ACNUY
AENEX
AFFNX
AGCGI
AHRSK
ALMA_UNASSIGNED_HOLDINGS
BR6
C45
CGR
CS3
CUY
CVF
DU5
EBS
ECM
EIF
EJD
F5P
H13
J5H
NPM
OVD
P2P
RTC
RTE
SJN
TEORI
X7M
ZGI
ZXP
ID FETCH-LOGICAL-c617t-3cb989ae27d12bc3721edec11d5b3e3f3a64d5d453032f1cc2b11975b3a486212
ISSN 0340-6245
IngestDate Mon Jul 21 05:47:04 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c617t-3cb989ae27d12bc3721edec11d5b3e3f3a64d5d453032f1cc2b11975b3a486212
PMID 18449416
ParticipantIDs pubmed_primary_18449416
PublicationCentury 2000
PublicationDate 2008-05-01
PublicationDateYYYYMMDD 2008-05-01
PublicationDate_xml – month: 05
  year: 2008
  text: 2008-05-01
  day: 01
PublicationDecade 2000
PublicationPlace Germany
PublicationPlace_xml – name: Germany
PublicationTitle Thrombosis and haemostasis
PublicationTitleAlternate Thromb Haemost
PublicationYear 2008
SSID ssj0016495
Score 2.0818083
SecondaryResourceType review_article
Snippet Use of recombinant human proteins has revolutionized medicine by providing over 200 highly purified hormones and proteins that effectively treat many inherited...
SourceID pubmed
SourceType Index Database
StartPage 874
SubjectTerms Animals
Antibodies - metabolism
Antibody Formation
Chemistry, Pharmaceutical
Cloning, Molecular
Dosage Forms
Drug Administration Routes
Drug Contamination
Drug Stability
Drug Storage
Humans
Polyethylene Glycols - chemistry
Protein Processing, Post-Translational
Recombinant Fusion Proteins - administration & dosage
Recombinant Fusion Proteins - biosynthesis
Recombinant Fusion Proteins - chemistry
Recombinant Fusion Proteins - immunology
Recombinant Fusion Proteins - therapeutic use
T-Lymphocytes - immunology
Title Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins
URI https://www.ncbi.nlm.nih.gov/pubmed/18449416
Volume 99
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFLY6kBAXBIwxxg_5wK3KmBM7P45o2qgmjQud1FtlO46arq2nNZu0nveH7z3HbkMZCLhEkZ1Ebb7P1nsv33uPkM8F1jTLyjQC2zWLeClMVMhMRYlOeGaYUNwlhZ1_TwcX_GwkRr3efUe1dNOoQ716NK_kf1CFMcAVs2T_Adn1Q2EAzgFfOALCcPwrjE99s5xmAm6-E51j9yoT7Ml6jskfFm6vtVdedNKt-ugLz5VTwvhWfa5oQ-3jd9PAo2u4ymLdEoyxT6SZW7Aol_Vyg9WlvbUre-v2m9ndeqP_IdVsWustHZLT6l43ZiZd1-_-N7tYyZldR3sru7xpTWqsc1HrSx9uDaGJfCMEDClZmFsQt_Uiw3bb9kPytBKdvTNv2_X8uqenKIIcDrCaJaq0xE-XASJXc4cv-Kq84G3m5p9ntypsh6kdsgO-BjZPxYiP_xKVcte5Z_1XQvJEevSl-5Ow-Kx_zJaD4gyV4UvywnsY9GtLl1ekZxavybNzr6HYJSPPGoqsoRvW0MbCkKFbrKG2oh3W0A5rqGMNDax5Qy5OT4bHg8j314g02K0NrEdV5IU0cVayWOkkixkAqxkrhUpMUiUyhcVbcgFmTlwxrWOFH51hUnJwhFm8R54s7MLsEypyVWWiQHFAxVmhcyMKJsH1yIzhKU_fkbftOxlftUVUxuFtHfx25j15viHVB_K0glVrPoIJ2KhPDqMHsvxdYQ
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Factors+that+contribute+to+the+immmunogenicity+of+therapeutic+recombinant+human+proteins&rft.jtitle=Thrombosis+and+haemostasis&rft.au=Mukovozov%2C+Ilya&rft.au=Sabljic%2C+Thomas&rft.au=Hortelano%2C+Gonzalo&rft.au=Ofosu%2C+Frederick+A&rft.date=2008-05-01&rft.issn=0340-6245&rft.volume=99&rft.issue=5&rft.spage=874&rft_id=info:doi/10.1160%2FTH07-11-0654&rft_id=info%3Apmid%2F18449416&rft_id=info%3Apmid%2F18449416&rft.externalDocID=18449416
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0340-6245&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0340-6245&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0340-6245&client=summon